Transgene’s combined general meeting 15
Category: dates
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.AACR 2023Download the poster herePoster Presentation
PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.AACR 2023Download the poster herePoster Presentation
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.AACR 2023Download the poster herePoster Presentation
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers
C. Le Tourneau, et al. AACR 2023 – Download the Poster
Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson, et al. AACR 2023 – Download the Poster
Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15